meta-analysis bias in location and selection of studies

BMJ

Volumn 316, Issue 7124, 1998, Pages 61-

  Egger, Matthias ^a   Smith, George Davey ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

DATA BASE; FINANCIAL MANAGEMENT; LANGUAGE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; THROMBOSIS; PUBLISHING;

META-ANALYSIS; PUBLICATION BIAS;

EID: 0032477417     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7124.61     Document Type: Article

References (53)

1. Eysenck H.J. An exercise in mega-silliness. Am Psychol 1978;33:517.
2. Chalmers I. Enkin M. Keirse M. Effective care during pregnancy and childbirth. Oxford:Oxford University Press, 1989.
3. Mann C. Meta-analysis in the breech. Science 1990;249:476–80.
4. Boden W.E. Meta-analysis in clinical trials reporting: has a tool become a weapon? Am J Cardiol 1992;69:681–6.
5. Mann C. Peto R. Statistician with a mission. Science 1990;249:479.
6. Chalmers T.C. Frank C.S. Reitman D. Minimizing the three stages of publication bias. JAMA 1990;263:1392–5.
7. Leizorovicz A. Haugh M.C. Chapuis F.-R. Samama M.M. Boissel J.-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913–20.
8. Nurmohamed M.T. Rosendaal F.R. Bueller H.R. Dekker E. Hommes D.W. Vandenbroucke J.P. et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152–6.
9. Simes R.J. Confronting publication bias: a cohort design for meta-analysis. Stat Med 1987;6:11–29.
10. Sterling T.D. Publication decisions and their possible effects on inferences drawn from tests of significance—or vice versa. J Am Stat Assoc 1959;54:30–34.
11. Rosenthal R. The “file drawer problem” and tolerance for null results. Psychol Bull 1979;86:638–41.
12. Light R.J. Pillemer D.B. Summing up. The science of reviewing research. Cambridge, M.A. London:Harvard University Press, 1984.
13. Easterbrook P.J. Berlin J.A. Gopalan R. Matthews D.R. Publication bias in clinical research. Lancet 1991;337:867–72.
14. Dickersin K. Min Y.L. Meinert C.L. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374–378.
15. Dickersin K. Min Y.L. NIH clinical trials and publication bias. Online J Curr Clin Trials [serial on line] 1993;28 Apr:Doc No 50.
16. Stern J.M. Simes R.J. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640–5.
17. Davidson R.A. Source of funding and outcome of clinical trials. J Gen Intern Med 1986;1:155–8.
18. Rochon P.A. Gurwitz J.H. Simms R.W. Fortin P.R. Felson D.T. Minaker K.L. et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157–163.
19. Manuscript guideline. Diabetologia 1984;25:4A.
20. Dickersin K. Chan S. Chalmers T.C. Sacks H.S. Smith H. Publication bias in clinical trials. Controlled Clinical Trials 1987;8:343–53.
21. Begg C.B. Berlin J.A. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989;81:107–15.
22. Grégoire G. Derderian F. Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol 1995;48:159–63.
23. Dickersin K. Scherer R. Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286–91.
24. Moher D. Fortin P. Jadad A.R. Jüni P. Klassen T. Le Lorier J. et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 1996;347:363–6.
25. Egger M. Zellweger T. Antes G. Randomised trials in German-language journals. Lancet 1996;347:1047–8.
26. Egger M. Zellweger-Zähner T. Schneider M. Junker C. Lengeler C. Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326–9.
27. Zielinski C. New equities of information in an electronic age. BMJ 1995;1480-1481.
28. Singh R. Singh S. Research and doctors. Lancet 1994;344:546.
29. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992;305:15–9.
30. Rossouw J.E. Lewis B. Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112–9.
31. Woodhill J.M. Palmer A.J. Leelarthaepin B. McGilchrist C. Blacket R.B. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol 1978;109:317–30.
32. Davey Smith G. Song F. Sheldon T.A. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:1367–73.
33. Savulescu J. Chalmers I. Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performances and accountability. BMJ 1996;313:1390–3.
34. Manninen V. Clinical results with gefibrozil and background to the Helsinki heart study. Am J Cardiol 1983;52:35–38 B.
35. Frick M.H. Elo O. Haapa K. Heinonen O.P. Heinsalmi P. Helo P. et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237–45.
36. Frick M.H. Heinonen O.P. Huttunen J.K. Koskinen P. Manttari M. Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki heart study frame population. Ann Med 1993;25:41–45.
37. Huston P. Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996;347:1024–6.
38. Tramèr M.R. Reynolds D.J.M. Moore R.A. McQuay H.J. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635–640.
39. Leizorovicz A. Haugh M.C. Boissel J.P. Meta-analysis and multiple publications of clinical trial reports. Lancet 1992;340:1102–3.
40. Felson D.T. Bias in meta-analytic research. J Clin Epidemiol 1992;45:885–92.
41. Peto R. Yusuf S. Collins R. Cholesterol-lowering trial results in their epidemiologic context. Circulation 1985;72 (suppl 3):451.
42. MacMahon S. Lowering cholesterol: effects on trauma death, cancer death and total mortality. Aust N Z J Med 1992;22:580–2.
43. Tang J.L. Armitage J.M. Lancaster T. Silagy C.A. Fowler G.H. Neil H.A.W. Systematic review of dietary intervention trials to lower cholesterol in free-living individuals. BMJ (in press).
44. Davey Smith G. Ebrahim S. Dietary change, cholesterol reduction and the public health: what does meta-analysis add? BMJ (in press).
45. Egger M. Davey Smith G. Schneider M. Minder C.E. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
46. Schulz K.F. Chalmers I. Hayes R.J. Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408–12.
47. Begg C.B. Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–99.
48. Egger M. Davey Smith G. Phillips A.N. Meta-analysis: principles and procedures. BMJ 1997;315:1533–7.
49. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405–8.
50. Egger M. Davey Smith G. Misleading meta-analysis. Lessons from “an effective, safe, simple” intervention that wasn't. BMJ 1995;310:752–4.
51. Pearn J. Publication: an ethical imperative. BMJ 1995;310:1313–5.
52. Cochrane Controlled Trials Register. In: The Cochrane Library [database on disk and CD ROM]. The Cochrane Collaboration. Issue 1. Oxford:Update Software, 1997. Updated quarterly.
53. Levy G. Publication bias: its implications for clinical pharmacology. Clin Pharmacol Ther 1992;52:115–9.